Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Ovapuldencel-T (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms AVOVA-1
- Sponsors AiVita Biomedical; Caladrius Biosciences; Lisata Therapeutics; NeoStem Oncology
- 06 Jun 2023 Primary endpoint (Overall survival) has not been met according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 21 Apr 2022 Planned End Date changed from 1 May 2022 to 1 Mar 2023.